NovoCure Limited (NASDAQ: NVCR - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 8,333,839 shares, a growth of 20.0% from the December 15th total of 6,943,501 shares. Currently, 7.9% of the company's shares are short sold. Based on an average
NovoCure Limited (NASDAQ: NVCR - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have assigned a buy recommendation to the company. The
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on th.
Despite an expected 7% revenue growth for FY2025, NVCR stock price was cut in half in 2025 following the disappointing adoption of Optune Lua in the US and Germany. Yet, the company pipeline has multiple shots on goal which could materially improve its revenue growth trajectory and profitability as early as 2027. Most key approvals and data readouts are expected in 2026, representing potential catalysts for a strong rebound.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer, will present on behalf of the company and address questions on Wednesday, January 14, at 9:45 a.m. PST. Mr. Leonard will be joined by William Doyle, Executive Chairman, and Christoph Brackmann, Chief Financial Officer, for one-on-one meetings.
Edgestream Partners L.P. raised its holdings in shares of NovoCure Limited (NASDAQ: NVCR) by 30.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 208,329 shares of the medical equipment provider's stock after purchasing an additional 48,057 shares during the period.
American Century Companies Inc. raised its stake in shares of NovoCure Limited (NASDAQ: NVCR) by 1,354.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,029,874 shares of the medical equipment provider's stock after acquiring an additional 959,079 shares during the quarter.
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. “During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their surv.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure's Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.c.
A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be acc.
NovoCure Limited ( NVCR ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Ingrid Goldberg - VP of Investor Relations William Doyle - Executive Chairman Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - President Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Kevin Joaquin - Evercore ISI Institutional Equities, Research Division Tanmay Patwardhan Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
NovoCure (NVCR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.28 per share a year ago.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product de.
Novocure Limited (NVCR) is rated BUY, driven by expanding regulatory approvals, breakthrough clinical results, and a robust late-stage pipeline in cancer therapy. NVCR's Tumor Treating Fields technology offers a differentiated, device-based approach to cancer treatment, with recent milestones in glioblastoma, lung, and pancreatic cancers. Upcoming Q3 results and regulatory updates, including METIS and PANOVA-3, are key catalysts, supported by strong liquidity and cautious financial management.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 2025 Meeting, Novocure will present pre-clinical data highlighting the potential of Tumor Treating Fields (TTFields) th.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three- and nine-month periods that ended September 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be.